267 related articles for article (PubMed ID: 12669961)
1. Direct evidence that polysorbate-80-coated poly(butylcyanoacrylate) nanoparticles deliver drugs to the CNS via specific mechanisms requiring prior binding of drug to the nanoparticles.
Kreuter J; Ramge P; Petrov V; Hamm S; Gelperina SE; Engelhardt B; Alyautdin R; von Briesen H; Begley DJ
Pharm Res; 2003 Mar; 20(3):409-16. PubMed ID: 12669961
[TBL] [Abstract][Full Text] [Related]
2. Indirect evidence that drug brain targeting using polysorbate 80-coated polybutylcyanoacrylate nanoparticles is related to toxicity.
Olivier JC; Fenart L; Chauvet R; Pariat C; Cecchelli R; Couet W
Pharm Res; 1999 Dec; 16(12):1836-42. PubMed ID: 10644071
[TBL] [Abstract][Full Text] [Related]
3. Interaction of poly(butylcyanoacrylate) nanoparticles with the blood-brain barrier in vivo and in vitro.
Alyaudtin RN; Reichel A; Löbenberg R; Ramge P; Kreuter J; Begley DJ
J Drug Target; 2001 Jun; 9(3):209-21. PubMed ID: 11697206
[TBL] [Abstract][Full Text] [Related]
4. [Transport of the hexapeptide dalargin across the hemato-encephalic barrier into the brain using polymer nanoparticles].
Aliautdin RN; Petrov VE; Ivanov AA; Kreuter J; Kharkevich DA
Eksp Klin Farmakol; 1996; 59(3):57-60. PubMed ID: 8974587
[TBL] [Abstract][Full Text] [Related]
5. Polysorbate-80 coating enhances uptake of polybutylcyanoacrylate (PBCA)-nanoparticles by human and bovine primary brain capillary endothelial cells.
Ramge P; Unger RE; Oltrogge JB; Zenker D; Begley D; Kreuter J; Von Briesen H
Eur J Neurosci; 2000 Jun; 12(6):1931-40. PubMed ID: 10886334
[TBL] [Abstract][Full Text] [Related]
6. Double-coated poly (butylcynanoacrylate) nanoparticulate delivery systems for brain targeting of dalargin via oral administration.
Das D; Lin S
J Pharm Sci; 2005 Jun; 94(6):1343-53. PubMed ID: 15858853
[TBL] [Abstract][Full Text] [Related]
7. [Drug delivery to the brain with nanoparticles].
Aliautdin RN; Kreuter J; Kharkevich DA
Eksp Klin Farmakol; 2003; 66(2):65-8. PubMed ID: 12962052
[TBL] [Abstract][Full Text] [Related]
8. Poly(n-butylcyanoacrylate) nanoparticles for oral delivery of quercetin: preparation, characterization, and pharmacokinetics and biodistribution studies in Wistar rats.
Bagad M; Khan ZA
Int J Nanomedicine; 2015; 10():3921-35. PubMed ID: 26089668
[TBL] [Abstract][Full Text] [Related]
9. Nanoparticles, a drug carrier system to pass the blood-brain barrier, permit central analgesic effects of i.v. dalargin injections.
Schröder U; Sabel BA
Brain Res; 1996 Feb; 710(1-2):121-4. PubMed ID: 8963650
[TBL] [Abstract][Full Text] [Related]
10. Effects of apolipoproteins on dalargin transport across the blood-brain barrier.
Shamenkov DA; Petrov VE; Alyautdin RN
Bull Exp Biol Med; 2006 Dec; 142(6):703-6. PubMed ID: 17603675
[TBL] [Abstract][Full Text] [Related]
11. Nanoparticle technology for delivery of drugs across the blood-brain barrier.
Schroeder U; Sommerfeld P; Ulrich S; Sabel BA
J Pharm Sci; 1998 Nov; 87(11):1305-7. PubMed ID: 9811481
[TBL] [Abstract][Full Text] [Related]
12. Transport of Poly(n-butylcyano-acrylate) nanoparticles across the blood-brain barrier in vitro and their influence on barrier integrity.
Rempe R; Cramer S; Hüwel S; Galla HJ
Biochem Biophys Res Commun; 2011 Mar; 406(1):64-9. PubMed ID: 21295549
[TBL] [Abstract][Full Text] [Related]
13. Passage of peptides through the blood-brain barrier with colloidal polymer particles (nanoparticles).
Kreuter J; Alyautdin RN; Kharkevich DA; Ivanov AA
Brain Res; 1995 Mar; 674(1):171-4. PubMed ID: 7773690
[TBL] [Abstract][Full Text] [Related]
14. Nanotoxicity of poly(n-butylcyano-acrylate) nanoparticles at the blood-brain barrier, in human whole blood and in vivo.
Kolter M; Ott M; Hauer C; Reimold I; Fricker G
J Control Release; 2015 Jan; 197():165-79. PubMed ID: 25445700
[TBL] [Abstract][Full Text] [Related]
15. Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier.
Kreuter J; Shamenkov D; Petrov V; Ramge P; Cychutek K; Koch-Brandt C; Alyautdin R
J Drug Target; 2002 Jun; 10(4):317-25. PubMed ID: 12164380
[TBL] [Abstract][Full Text] [Related]
16. Cytotoxicity and apoptotic gene expression in an in vitro model of the blood-brain barrier following exposure to poly(butylcyanoacrylate) nanoparticles.
Hall AM; Hemmer R; Spaulding R; Wetzel HN; Curcio J; Sabel BA; Henrich-Noack P; Pixley S; Hopkins T; Boyce RL; Schultheis PJ; Haik KL
J Drug Target; 2016 Aug; 24(7):635-44. PubMed ID: 26707984
[TBL] [Abstract][Full Text] [Related]
17. The first step into the brain: uptake of NIO-PBCA nanoparticles by endothelial cells in vitro and in vivo, and direct evidence for their blood-brain barrier permeation.
Weiss CK; Kohnle MV; Landfester K; Hauk T; Fischer D; Schmitz-Wienke J; Mailänder V
ChemMedChem; 2008 Sep; 3(9):1395-403. PubMed ID: 18613205
[TBL] [Abstract][Full Text] [Related]
18. Targeted delivery of tacrine into the brain with polysorbate 80-coated poly(n-butylcyanoacrylate) nanoparticles.
Wilson B; Samanta MK; Santhi K; Kumar KP; Paramakrishnan N; Suresh B
Eur J Pharm Biopharm; 2008 Sep; 70(1):75-84. PubMed ID: 18472255
[TBL] [Abstract][Full Text] [Related]
19. Delivery of loperamide across the blood-brain barrier with polysorbate 80-coated polybutylcyanoacrylate nanoparticles.
Alyautdin RN; Petrov VE; Langer K; Berthold A; Kharkevich DA; Kreuter J
Pharm Res; 1997 Mar; 14(3):325-8. PubMed ID: 9098875
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of oral dalargin-loaded nanoparticle delivery across the blood-brain barrier.
Schroeder U; Sommerfeld P; Sabel BA
Peptides; 1998; 19(4):777-80. PubMed ID: 9622035
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
